Erin Quirk - Jan 26, 2022 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
President, CMO and Head of R&D
Signature
/s/ Bryan Yoon, as Attorney-in-Fact for Erin Quirk
Stock symbol
TERN
Transactions as of
Jan 26, 2022
Transactions value $
$0
Form type
4
Date filed
1/28/2022, 08:02 PM
Previous filing
Sep 30, 2021
Next filing
Feb 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Award $0 +92.5K $0.00 92.5K Jan 26, 2022 Common Stock 92.5K $5.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.